Perspective Therapeutics Inc (AMEX: CATX) on Friday, plunged -4.78% from the previous trading day, before settling in for the closing price of $2.51. Within the past 52 weeks, CATX’s price has moved between $1.60 and $16.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 1.39%. The company achieved an average annual earnings per share of 7.47%. With a float of $54.06 million, this company’s outstanding shares have now reached $74.05 million.
The extent of productivity of a business whose workforce counts for 140 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Perspective Therapeutics Inc (CATX) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Perspective Therapeutics Inc is 27.18%, while institutional ownership is 66.43%. The most recent insider transaction that took place on Mar 28 ’25, was worth 49,384. In this transaction Chief Executive Officer of this company bought 22,026 shares at a rate of $2.24, taking the stock ownership to the 59,383 shares. Before that another transaction happened on Mar 28 ’25, when Company’s Chief Executive Officer bought 4,650 for $2.21, making the entire transaction worth $10,288. This insider now owns 4,650 shares in total.
Perspective Therapeutics Inc (CATX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.62% during the next five years compared to -9.86% drop over the previous five years of trading.
Perspective Therapeutics Inc (AMEX: CATX) Trading Performance Indicators
Perspective Therapeutics Inc (CATX) is currently performing well based on its current performance indicators. A quick ratio of 17.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 120.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Perspective Therapeutics Inc (CATX)
The latest stats from [Perspective Therapeutics Inc, CATX] show that its last 5-days average volume of 0.91 million was superior to 0.8 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 42.32%. Additionally, its Average True Range was 0.24.
During the past 100 days, Perspective Therapeutics Inc’s (CATX) raw stochastic average was set at 29.92%, which indicates a significant decrease from 34.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 125.51% in the past 14 days, which was higher than the 86.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.29, while its 200-day Moving Average is $6.61. Now, the first resistance to watch is $2.50. This is followed by the second major resistance level at $2.61. The third major resistance level sits at $2.66. If the price goes on to break the first support level at $2.34, it is likely to go to the next support level at $2.28. Assuming the price breaks the second support level, the third support level stands at $2.17.
Perspective Therapeutics Inc (AMEX: CATX) Key Stats
Market capitalization of the company is 177.41 million based on 74,228K outstanding shares. Right now, sales total 1,450 K and income totals -79,280 K. The company made 340 K in profit during its latest quarter, and -18,180 K in sales during its previous quarter.
